Anginox MR 35 mg (Tablet (Modified Release)) is a brand of the generic Trimetazidine Dihydrochloride. It is manufactured by General Pharmaceuticals Ltd..

Tablet (Modified Release) Anginox MR Tablet (Modified Release)

35 mg

Pack Size & Price:

Unit Price: ৳ 6.00

Indications

Long-term treatment of Ischaemic heart disease (angina pectoris, sequelae of infarction).

Therapeutic Class

Other Anti-anginal & Anti-ischaemic drugs

Pharmacology

Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation. High fatty acid oxidation rates are detrimental during ischemia due to an inhibition of glucose oxidation leading to uncoupling of glycolysis and an increase in proton production, which has the potential to accelerate sodium and calcium overload in the heart. This leads to an exacerbation of ischemic injury and decreased cardiac efficiency during reperfusion.

Dosage & Administration

One 20 mg tablet thrice daily after meals. No dosage adjustments are required in patients with impaired renal and hepatic function.

One 35 mg modified release tablet twice daily at mealtimes in the morning and evening.

Interaction

No drug interactions have so far been reported. In particular, no interactions of Trimetazidine with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis have been reported.

Contraindications

Hypersensitivity to Trimetazidine Dihydrochloride.

Side Effects

Trimetazidine is safe and well tolerated. The most commonly encountered side effects are gastric discomfort, nausea, headache and vertigo. However, the side effects are mild and non-specific.

Pregnancy & Lactation

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Nursing Mothers: There is no information on the secretion of Trimetazidine into breast milk. However, breast feeding should be discontinued if the use of Trimetazidine is considered essential.

Storage Conditions

Store in a cool and dry place, protect from light and moisture. Keep out of the reach of children.